Skye Bioscience, Inc.

SKYE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$12,755-$17,625-$11,103-$9,746
Dep. & Amort.$179$187$177$175
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$2,202$2,089
Change in WC-$2,611$4,748-$461-$869
Other Non-Cash$1,823$1,944-$9,176,295$178
Operating Cash Flow-$13,364-$10,746-$9,185,480-$8,173
Investing Activities
PP&E Inv.$0$0-$6,312-$50
Net Acquisitions$91$89$0-$1,218
Inv. Purchases$7,876-$11,944-$12,802,650$0
Inv. Sales/Matur.$0$0$0$1,358
Other Inv. Act.$0$0$0$0
Investing Cash Flow$7,967-$11,855-$12,808,962$90
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$18$0-$83,557
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$83,562
Financing Cash Flow$0$18$0$6
Forex Effect$0$0$0$0
Net Chg. in Cash-$5,397-$22,583-$21,994,442-$8,077
Supplemental Information
Beg. Cash$23,838$46,421$68,415,741$76,493
End Cash$18,441$23,838$46,421,299$68,416
Free Cash Flow-$13,364-$10,746-$9,191,792-$8,223